Compare Amgen, Inc. (AMGN) vs Centrus Energy Corp (LEU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Centrus Energy Corp — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Centrus Energy Corp trades at $170.33 (market cap $3.37B). The key difference: Amgen, Inc. is far larger — about 58.2× Centrus Energy Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| AMGN | LEU | |
|---|---|---|
Market Cap | $196.12B | $3.37B |
Sector | Health | Energy |
52-Week High | $388.16 | $436.00 |
52-Week Low | $271.18 | $146.61 |
Enterprise Value | $241.41B | $2.68B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Centrus Energy (LEU) trades at $171.05, down 1.45% on the day, with a neutral technical outlook. The company recently secured a major Department of Energy contract valued over $1 billion and is set to join the S&P SmallCap 600 index. While Q1 2026 earnings beat expectations, Q4 2025 was a significant miss. Valuation ratios appear elevated with a P/E of 62.2 and P/S of 8.05. Operating cash flow was positive in 2025 but turned negative in 2026 projections.
The outlook is mixed; strong government contracts and index inclusion provide tailwinds, but high valuation and inconsistent earnings pose risks. Analyst consensus is a Buy with a $224.50 price target, suggesting potential upside, though execution on new contracts and profitability trends will be critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
